Sydow, Hanna http://orcid.org/0000-0001-9116-9204
Prescher, Sandra
Koehler, Friedrich
Koehler, Kerstin
Dorenkamp, Marc
Spethmann, Sebastian
Westerhoff, Benjamin
Wagner, Christoph J.
Liersch, Sebastian
Rebscher, Herbert
Wobbe-Ribinski, Stefanie
Rindfleisch, Heike
Müller-Riemenschneider, Falk
Willich, Stefan N.
Reinhold, Thomas
Funding for this research was provided by:
bundesministerium für bildung, wissenschaft, forschung und technologie (13KQ0904A, 13KQ0904B, 13KQ1104A)
Charité - Universitätsmedizin Berlin
Article History
Received: 28 June 2021
Accepted: 24 November 2021
First Online: 11 December 2021
Declarations
:
: Hanna Sydow has nothing to declare. Sandra Prescher has nothing to declare. Friedrich Koehler reports grants from the German Federal Ministry of Education and Research and grants from the Federal Ministry of Economic Affairs and Energy for conducting the clinical trials. He reports personal fees for advisory boards from Abbott and Sanofi-Aventis. He received fees for lectures from Boston Scientific, Sanofi-Aventis Deutschland GmbH, Novartis, Linde/Saúde, Roche Pharma AG, Amgen GmbH, and Astra Zeneca outside the submitted work. Kerstin Koehler has nothing to declare. Marc Dorenkamp has nothing to declare. Sebastian Spethmann reports personal fees for lectures from Pfizer, Novartis, Berlin Chemie AG, Bristol-Myers Squibb GmbH & Co. KGaA, BAYER VITAL GmbH and Astra Zeneca outside the submitted work. Furthermore, he is a member of the Commission Digital Health of the German Association for Internal Medicine (DGIM). Benjamin Westerhoff has nothing to declare. Christoph J. Wagner has nothing to declare. Sebastian Liersch has nothing to declare. Herbert Rebscher has nothing to declare. Stefanie Wobbe-Ribinski has nothing to declare. Heike Rindfleisch has nothing to declare. Falk Müller-Riemenschneider has no conflicts of interest to declare. Stefan N. Willich has no conflicts of interest to declare. Thomas Reinhold has nothing to declare.
: Written approval from the appropriate ethics committees was obtained.
: All patients provided written informed consent at the start of the TIM-HF2 trial to receive health cost claim data from their statutory health insurance.
: Not applicable.